Hoth Therapeutics Inc (HOTH) Stock Price, Quote & News

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for th...

Industry: Biotechnology

Sector: Healthcare

Phone: (646) 756-2997

Website: hoththerapeutics.com

Address:

1177 Avenue of the Americas, Suite 5066 5th Floor, New York, United States

TradingLaboratory Jul. 6 at 12:50 AM

$HOTH More news on the way ?

0 · Reply

Atlas_Portfolio Jul. 5 at 6:05 PM

$HOTH https://bremcakes.beehiiv.com/ Sign up for free newsletters including fundamental and technical analysis of your favorite stocks/crypto

0 · Reply

Pratik2024 Jul. 3 at 5:39 PM

$GFAI $HOTH $KULR $MWYN MWYN - only 2 million market float and 72% owns by the insiders. Went to $11 from $4 after IPO’d. Reloading time. Happy 4th of July. See at moon on Monday.

1 · Reply

eltonfitz Jul. 3 at 3:38 PM

$HOTH Hi All, just got the AGM Proxy. Saw the item to approve an amendment to increase the number of shares reserved for issuance (from 1 mill to approx 3 mill). Can anyone clarify? This part of an incentive plan versus anything more "problematic"?

1 · Reply

Pratik2024 Jul. 3 at 12:11 PM

$CURV $GFAI $HOTH $KULR $MWYN Pre-market move for MWYN.

0 · Reply

Pratik2024 Jul. 3 at 3:45 AM

$CURV $GFAI $HOTH $KULR $MWYN MWYN - only 2 million market float and 72% owns by the insiders. Went to $11 from $4 after IPO’d. Reloading time.

0 · Reply

canadianpennystockhunter Jul. 2 at 10:02 PM

$HOTH I HIGHLY, recommend doing your research on $HOTH, especially the CEO Robb Knie. He alone should have investors EXTREMELY bullish on the company. https://hoththerapeutics.com/about-us/our-team/robb-knie/

0 · Reply

The_Iceman_ Jul. 2 at 7:40 PM

$HOTH Undervalued.

1 · Reply

canadianpennystockhunter Jul. 2 at 2:58 PM

$HOTH

0 · Reply

Pratik2024 Jul. 2 at 2:29 PM

$GFAI $HOTH $KULR $MWYN $BREA $MWYN set to buy

0 · Reply

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Jun 24, 2025, 10:36 AM EDT - 12 days ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 23, 2025, 8:03 AM EDT - 13 days ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Jun 18, 2025, 1:34 PM EDT - 18 days ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Jun 18, 2025, 8:22 AM EDT - 18 days ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 16, 2025, 8:00 AM EDT - 20 days ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Jun 12, 2025, 9:17 AM EDT - 24 days ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Jun 11, 2025, 8:28 AM EDT - 25 days ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 5, 2025, 8:12 AM EDT - 4 weeks ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

May 12, 2025, 7:30 AM EDT - 7 weeks ago

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Apr 17, 2025, 8:01 AM EDT - 2 months ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 15, 2025, 8:19 AM EDT - 2 months ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 2, 2025, 8:02 AM EDT - 3 months ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Apr 2, 2025, 7:58 AM EDT - 3 months ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Mar 31, 2025, 4:45 PM EDT - 3 months ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Mar 26, 2025, 8:02 AM EDT - 3 months ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 18, 2025, 8:06 AM EDT - 3 months ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Mar 10, 2025, 8:02 AM EDT - 4 months ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Mar 5, 2025, 1:40 PM EST - 4 months ago

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Mar 4, 2025, 8:16 AM EST - 4 months ago

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Feb 10, 2025, 8:22 AM EST - 5 months ago

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Jan 24, 2025, 8:29 AM EST - 5 months ago

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jan 21, 2025, 8:29 AM EST - 5 months ago

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Jan 17, 2025, 8:29 AM EST - 6 months ago

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Jan 8, 2025, 1:27 PM EST - 6 months ago

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Jan 7, 2025, 11:53 AM EST - 6 months ago

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Jan 7, 2025, 8:29 AM EST - 6 months ago

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Dec 26, 2024, 7:58 AM EST - 6 months ago

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Nov 20, 2024, 7:38 AM EST - 8 months ago

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Oct 29, 2024, 12:43 PM EDT - 8 months ago

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Oct 15, 2024, 6:38 AM EDT - 9 months ago

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Sep 17, 2024, 7:57 AM EDT - 10 months ago

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Sep 5, 2024, 10:32 AM EDT - 10 months ago

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Sep 5, 2024, 8:03 AM EDT - 10 months ago

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Aug 15, 2024, 8:04 AM EDT - 11 months ago

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Jul 16, 2024, 8:31 AM EDT - 1 year ago

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Jun 10, 2024, 8:11 AM EDT - 1 year ago

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

May 1, 2024, 8:00 AM EDT - 1 year ago

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

Mar 27, 2024, 2:00 PM EDT - 1 year ago

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

Mar 27, 2024, 8:27 AM EDT - 1 year ago

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Mar 19, 2024, 8:21 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Feb 29, 2024, 8:38 AM EST - 1 year ago

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

Feb 26, 2024, 8:11 AM EST - 1 year ago

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

Feb 13, 2024, 11:45 AM EST - 1 year ago

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

Jan 18, 2024, 8:20 AM EST - 1 year ago

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

Dec 5, 2023, 8:33 AM EST - 1 year ago

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies

Nov 14, 2023, 8:37 AM EST - 1 year ago

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT

Nov 10, 2023, 8:00 AM EST - 1 year ago

Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023

Oct 5, 2023, 10:03 AM EDT - 1 year ago

Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery

TradingLaboratory Jul. 6 at 12:50 AM

$HOTH More news on the way ?

0 · Reply

Atlas_Portfolio Jul. 5 at 6:05 PM

$HOTH https://bremcakes.beehiiv.com/ Sign up for free newsletters including fundamental and technical analysis of your favorite stocks/crypto

0 · Reply

Pratik2024 Jul. 3 at 5:39 PM

$GFAI $HOTH $KULR $MWYN MWYN - only 2 million market float and 72% owns by the insiders. Went to $11 from $4 after IPO’d. Reloading time. Happy 4th of July. See at moon on Monday.

1 · Reply

eltonfitz Jul. 3 at 3:38 PM

1 · Reply

Pratik2024 Jul. 3 at 12:11 PM

$CURV $GFAI $HOTH $KULR $MWYN Pre-market move for MWYN.

0 · Reply

Pratik2024 Jul. 3 at 3:45 AM

$CURV $GFAI $HOTH $KULR $MWYN MWYN - only 2 million market float and 72% owns by the insiders. Went to $11 from $4 after IPO’d. Reloading time.

0 · Reply

canadianpennystockhunter Jul. 2 at 10:02 PM

0 · Reply

The_Iceman_ Jul. 2 at 7:40 PM

$HOTH Undervalued.

1 · Reply

canadianpennystockhunter Jul. 2 at 2:58 PM

$HOTH

0 · Reply

Pratik2024 Jul. 2 at 2:29 PM

$GFAI $HOTH $KULR $MWYN $BREA $MWYN set to buy

0 · Reply

vjtweet Jul. 2 at 3:56 AM

$HOTH for tomorrow.

1 · Reply

Biotechs5454 Jul. 1 at 9:59 PM

$HOTH Stand alone HT-001 presentation filed last week. Come to your own conclusions as to why. Full presentation still on website. Stand alone presentation still does not have details on the double blind portion of the study. Some preliminary data has to be soon one would think. Jmho.

2 · Reply

Mack43 Jul. 1 at 8:11 PM

$HOTH slowly and quietly climbing!

0 · Reply

Tino321 Jun. 30 at 9:15 PM

$HOTH hope we all get minimum 3x from this stock. Stay patient and be willing to lose it all 🤣 🤷‍♂️

1 · Reply

WallStreetReporter Jun. 30 at 6:46 PM

$HOTH ready to EXPLODE next!!! Look at this #BREAKOUT #STockCharts!!! 💰💰💰 1 hr charts inverse head & shoudler bottom just like $SYTA had on thrusday before BOOM!! $SYTA $HOTH 2 hottest stocks THIS week🚀🚀🚀 @BreakoutStocks @PeloSwing @MrZackMorris @BillAckman

1 · Reply

Pratik2024 Jun. 30 at 4:13 PM

$CURV $GFAI $HOTH $KULR Sold $KULR to buy back. Buying $MWYN Adding $CURV

0 · Reply

Ticker_Pumper Jun. 30 at 2:47 PM

$HOTH watch list is growing… buckle your chin straps!!!

0 · Reply

Pratik2024 Jun. 30 at 2:09 PM

$CURV $GFAI $HOTH $KULR KULR and GFAI looks ok. HOTH needs a PR. CURV shorters will go away soon. Loading more.

0 · Reply

Pratik2024 Jun. 29 at 2:01 PM

$CURV $GFAI $HOTH $KULR Hope better week ahead.

0 · Reply

The_Iceman_ Jun. 28 at 11:56 PM

$HOTH You want big % gains between Summer 2025 and Summer 2027? Buy stock in Hoth Therapeutics now and hold on. $3 by Christmas! 👑

0 · Reply

RaphaelRapoport Jun. 27 at 7:48 PM

$HOTH What happened to this stock this week?

3 · Reply

Pratik2024 Jun. 27 at 6:07 PM

$GFAI $HOTH $KULR $CURV Today KULR. Loading CURV. Holding GFAI and HOTH.

0 · Reply

Market Cap	15.98M
Revenue (ttm)	0.00
Net Income (ttm)	-8.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	132,900
Avg Vol	1,301,578
Day's Range	N/A - N/A
Shares Out	13.21M
Stochastic %K	46%
Beta	0.67
Analysts	Strong Sell
Price Target	$4.50